
Why Real-World Evidence Matters: Closing the Data Gap on M-TEER Durability
Real-world evidence (RWE) has become one of the most important tools in clinical research because it shows how therapies perform in everyday practice, across broad populations and over many years. But not all real-world data is built to answer every question. Few areas show the need for real-world evidence more

Moderate Aortic Stenosis (AS) With At-Risk Features
ACTIVATE AS is a prospective, multicenter observational study using the CardioCare® platform to identify and follow patients with moderate AS. Participants receive heart team evaluation, core lab echo, natriuretic peptide testing and CT calcium scoring. Enrollment is expected to begin in 2027.
The egnite 2026 Benchmark Report
The report tracks heart failure and structural heart care across 47 U.S. health systems, 830 facilities, and more than 15.7 million de-identified patients. Read the full report.

Rethinking the Aortic Stenosis Pipeline
Aortic stenosis care is shifting from a reactive to a proactive model. Emerging clinical evidence supports earlier identification, closer monitoring, and intentional patient management across the disease continuum. As treatment thresholds evolve, health systems need scalable approaches to identify at-risk patients, close treatment gaps, and ensure timely access to specialist

Cath Lab Capacity is Up—But Structural Heart Procedures Are Being Outpaced by Other Interventions
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient
egnite Registry
Power Your Research with the egnite Registry
Longitudinal clinical data designed for advanced real-world research